Published: August 1, 2025
(For eligible participants, study-related treatments, medical exams, and follow-ups during the study period are fully covered/funded by the respective research teams.)
1. Open-Label, Single-Center Phase I Trial of NY-ESO-1 Antigen-Specific High-Affinity TCR-Transduced Autologous T Cells (Super1 TCR-T) for NY-ESO-1-Positive Advanced Solid Tumors
● Patient Population: Solid tumors (NY-ESO-1-positive advanced solid tumors)
● Principal Investigator (PI): Zhang Xing
● Contact Information:
○Prof. Zhang Xing: Mon PM, Wed & Thu AM (Yuexiu Campus)
○Prof. Peng Ruiqing: Thu PM (Yuexiu Campus)
○Prof. Pan Qiuzhong: Wed PM (Huangpu Campus)
2. Phase II Trial of Neoadjuvant Chemotherapy + Camrelizumab for Thoracic Esophageal Squamous Cell Carcinoma with Cervical Lymph Node Metastasis
● Patient Population: Esophageal cancer (thoracic esophageal squamous cell carcinoma with cervical lymph node metastasis)
● Principal Investigator (PI): Zhang Xu
● Contact: Assistant Su, Tel: +86-13640843744
3. Phase II Trial of Neoadjuvant Chemotherapy + Camrelizumab for Elderly Patients with Locally Advanced Esophageal Squamous Cell Carcinoma
● Patient Population: Esophageal cancer (elderly patients with locally advanced esophageal squamous cell carcinoma)
● Principal Investigator (PI): Zhang Xu
● Contact: Assistant Su, Tel: +86-13640843744
4. Phase I Trial of EBV mRNA Vaccine (WGc-043 Injection) in EBV-Positive Relapsed or Refractory Lymphoma: Safety, Tolerability, PK, Immunogenicity, and Preliminary Anti-Tumor Activity
● Patient Population: EBV-positive relapsed/refractory lymphoma
● Principal Investigator (PI): Cai Qingqing
● Contact: Assistant Yang, Tel: +86-18826275445
5. Phase 3, Randomized, Double-Blind, Multicenter Study of SONROTOCLAX + Zanubrutinib vs. Placebo + Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma
● Patient Population: Relapsed/refractory mantle cell lymphoma
● Principal Investigator (PI): Cai Qingqing
● Contact: Assistant Yang, Tel: +86-18826275445
6. SOUNDTRACK-B: Modular, Single-Arm, Multicenter, Open-Label Phase II Study of AZD0486 in Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma
● Patient Population: Relapsed/refractory B-cell non-Hodgkin’s lymphoma
● Principal Investigator (PI): Cai Qingqing
● Contact: Assistant Yang, Tel: +86-18826275445
Note:
For detailed inclusion/exclusion criteria or full outpatient schedules, please visit the official SYSUCC Patient Recruitment System or contact the
designated research assistants.
For more recruitment information, visit: http://www.sysucc.org.cn/node/10932
WhatsApp
Address
Mailing Form
Languages
English
WhatsApp